Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
3D cell culturing platform allows study of idiopathic pulmonary fibrosis

3D cell culturing platform allows study of idiopathic pulmonary fibrosis

Updated mapping of the human genetic architecture of COVID-19

Updated mapping of the human genetic architecture of COVID-19

A possible protective genetic polymorphism in COVID-19

A possible protective genetic polymorphism in COVID-19

Repeated injury to the epithelial tissue of airways causes "biological aging" of stem cells

Repeated injury to the epithelial tissue of airways causes "biological aging" of stem cells

Researchers receive $12.8M renewal grant to reveal how smoking causes distinct lung diseases

Researchers receive $12.8M renewal grant to reveal how smoking causes distinct lung diseases

New model shows how dysfunction in the air sacs initiates fibrotic cascade

New model shows how dysfunction in the air sacs initiates fibrotic cascade

Study suggests a novel therapeutic target to reverse lung fibrosis

Study suggests a novel therapeutic target to reverse lung fibrosis

Single-cell RNA sequencing reveals cells that could protect from fatal lung disease

Single-cell RNA sequencing reveals cells that could protect from fatal lung disease

PET radiotracer can noninvasively identify and monitor pulmonary fibrosis

PET radiotracer can noninvasively identify and monitor pulmonary fibrosis

Antibiotics provide no benefit for patients with idiopathic pulmonary fibrosis, study finds

Antibiotics provide no benefit for patients with idiopathic pulmonary fibrosis, study finds

Shared genetic architecture between COVID-19 severity and other health conditions

Shared genetic architecture between COVID-19 severity and other health conditions

A modified protein mediates development of lung fibrosis after cadmium/carbon black exposure

A modified protein mediates development of lung fibrosis after cadmium/carbon black exposure

Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis

Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis

Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis

Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis

Study highlights the epigenetics of life at high altitudes

Study highlights the epigenetics of life at high altitudes

Bernese researchers develop a second generation lung-on-chip

Bernese researchers develop a second generation lung-on-chip

ACE2 agonist C21 relieves respiratory difficulty in COVID-19

ACE2 agonist C21 relieves respiratory difficulty in COVID-19

Owlstone Medical introduces breath biopsy panel for respiratory diseases

Owlstone Medical introduces breath biopsy panel for respiratory diseases

BU researchers awarded $2.4 million NIH grant to study idiopathic pulmonary fibrosis

BU researchers awarded $2.4 million NIH grant to study idiopathic pulmonary fibrosis

New collaborative study to address key questions about COVID-19

New collaborative study to address key questions about COVID-19

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.